Overview

A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors

Status:
Not yet recruiting
Trial end date:
2025-03-15
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label study to assess the safety and preliminary efficacy and to determine the maximum tolerated dose (MTD) or maximum administration dose (MAD) and recommended Phase 2 doses (RP2D) of PRJ1-3024 in subjects with relapsed/refractory solid tumors. The study consists of two parts, one is a 3+3 dose escalation study and another is a pharmaceutical extension of RP2D.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Zhuhai Yufan Biotechnologies Co., Ltd